Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12.


Aside from bidimensional measurements from conventional contrast-enhanced MRI, there are no validated or FDA-qualified imaging biomarkers for high-grade gliomas. However, advanced functional MRI techniques, including perfusion- and diffusion-weighted MRI, have demonstrated much potential for determining prognosis, predicting therapeutic response, and assessing early treatment response. They may also prove useful for differentiating pseudoprogression from true progression after temozolomide chemoradiation and pseudoresponse from true response after anti-angiogenic therapy. This review will highlight recent developments using these techniques and emphasize the need for technical standardization and validation in prospective studies in order for these methods to become incorporated into standard-of-care imaging for brain tumor patients.

Keywords: diffusion; high-grade glioma; imaging biomarker; perfusion; physiologic imaging.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Brain Neoplasms / diagnostic imaging
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / therapy
  • Combined Modality Therapy
  • Glioblastoma / diagnostic imaging
  • Glioblastoma / pathology*
  • Glioblastoma / therapy
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Prognosis